Linkage Biosciences Raises $2M in Series B Round | GenomeWeb

Linkage Biosciences said this week that it has closed a Series B financing round worth $2 million.

Linkage markets the LinkSeq HLA product line, which uses a proprietary software and chemistry platform in conjunction with real-time PCR instrumentation for HLA typing. According to the company, LinkSeq is an end-point PCR process that uses allele-specific amplification combined with SYBR Green to detect PCR products on the instrument using melt-curve analysis.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.